Couselo-Seijas M, Agra-Bermejo RM, Fernández AL, et al. - In view of the information that glucose uptake by epicardial adipose tissue is improved by dapagliflozin (a sodium-glucose co-transporter 2 inhibitor), but under hypoxia conditions, ie, coronary artery disease (CAD), or lipogenesis, its metabolism might increase the lactate generation and acidosis and as a result expand adipose tissue, and because a correlation of lactate secreted by adipose tissue with tissue stress and inflammation has been reported, researchers assessed glucose metabolism by epicardial fat from CAD as well as their regulation by dapagliflozin. This study included 49 patients who were treated with open-heart surgery. Findings revealed improvement in glucose metabolism, without lipogenesis-involved gene regulation or lactate generation, as a result of treatment with dapagliflozin, mainly in patients with CAD. This is indicative of the improvement of glucose oxidation metabolism that can add to cardiovascular benefits.